US 11,932,638 B2
Ion channel inhibitor compounds for cancer treatment
Sylvain Routier, Tigy (FR); Frédéric Buron, Olivet (FR); Nuno Rodrigues, Aubiere (FR); Gaëlle Fourriere-Grandclaude, Chelles (FR); Christophe Vandier, La Riche (FR); Aurélie Chantome, Tours (FR); Marie Potier-Cartereau, La Riche (FR); Maxime Gueguinou, Tours (FR); and Séverine Marionneau-Lambot, Thouare sur Loire (FR)
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE, Paris (FR); UNIVERSITE D'ORLEANS, Orleans (FR); UNIVERSITE DE TOURS, Tours (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE SCIENTIFIQUE (INSERM), Paris (FR); and CHU NANTES, Nantes (FR)
Appl. No. 16/615,947
Filed by Centre National de la Recherche Scientifique, Paris (FR); Universite d'Orleans, Orleans (FR); Université de Tours, Tours (FR); Institut National de la Santé et de la Recherche Médicale (INSERM), Paris (FR); and CHU Nantes, Nantes (FR)
PCT Filed May 23, 2018, PCT No. PCT/EP2018/063543
§ 371(c)(1), (2) Date Feb. 26, 2020,
PCT Pub. No. WO2018/215557, PCT Pub. Date Nov. 29, 2018.
Claims priority of application No. 17 54564 (FR), filed on May 23, 2017.
Prior Publication US 2021/0009581 A1, Jan. 14, 2021
Int. Cl. C07D 471/04 (2006.01); A61P 35/04 (2006.01); C07D 487/04 (2006.01); C07D 491/048 (2006.01); C07D 495/04 (2006.01); C07D 513/04 (2006.01)
CPC C07D 471/04 (2013.01) [A61P 35/04 (2018.01); C07D 487/04 (2013.01); C07D 491/048 (2013.01); C07D 495/04 (2013.01); C07D 513/04 (2013.01)] 7 Claims
 
1. A method for treating breast cancer, melanoma, prostate cancer, colorectal cancer, or urotherial carcinoma, said method comprising administering to a subject in need thereof a compound having formula (III-4):

OG Complex Work Unit Chemistry
where:
either X1 is a nitrogen atom and X2 is a C(R4) group,
or X1 is a C(R5) group and X2 is a nitrogen atom,
or X1 and X2 are a nitrogen atom,
R4 and R5 each independently being H or a substituent selected from the group consisting of: halogen atoms, (C1-C6)(cyclo)alkyl groups, NRaRb groups, and ORa groups, Ra and Rb each independently being H or (C1-C6)alkyl group,
R1 is H, a (C1-C6)alkyl group or a radical selected from the group consisting of: —ORa, —NHRa, —NRaRb, —NH—C(═O)Ra, —C(═O)Ra, —C(═O)ORa, —NH—CN, —C(═O)NRaRb, Cl, F, CN and nitrogen-containing and/or oxygen-containing heterocycles, said nitrogen-containing heterocycles and/or said oxygen-containing heterocycles having 5 atoms, and wherein Ra and Rb each independently being H, a (C1-C6)alkyl group or (C3-C6)cycloalkyl group;
R2 and R3 are each independently H or a substituent selected from the group consisting of: halogen atoms, (C1-C6)(cyclo)alkyl groups, NRaRb groups, and ORa groups, Ra and Rb each independently being H or (C1-C6)alkyl group;
said compound of formula (III-4) being in pure stereoisomer form, or in the form of a mixture of enantiomers and/or diastereoisomers.